Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.

Drug metabolism and disposition: the biological fate of chemicals - 1 Dec 2006

Kumar Vikas, Wahlstrom Jan L, Rock Dan A, Warren Chad J, Gorman Lee A, Tracy Timothy S

Abstract excerpt

Drug-drug interactions may cause serious adverse events in the clinical setting, and the cytochromes P450 are the enzyme system most often implicated in these interactions. Cytochrome P450 2C is the second most abundant subfamily of cytochrome P450 enzymes and is responsible for metabolism of almost 20% of currently marketed drugs. The most abundant isoform of this subfamily is CYP2C9, which is the major...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Genotype

Share to In Vitro Techniques

Share to Pharmacogenetics

Share to Phenytoin

Share to Warfarin

Source

Identifiers

PMID: 16963489
DOI: 10.1124/dmd.106.010926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.PMID 16963489Read ↗

Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.Semantic proximity Read ↗

A model-based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs.Semantic proximity Read ↗

CYP2C9 genotype as a predictor of drug disposition in humans.Semantic proximity Read ↗

Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.Semantic proximity Read ↗

Drugs as CYP3A Probes, Inducers, and InhibitorsSemantic proximity Read ↗

Use of Phenotypically Poor Metabolizer Individual Donor Human Liver Microsomes To Identify Selective Substrates of UGT2B10.Semantic proximity Read ↗

The impact of CYP2C19 genotype on phenoconversion by concomitant medicationSemantic proximity Read ↗

Use of Probe Drugs as Predictors of Drug Metabolism in HumansSemantic proximity Read ↗

Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data.Semantic proximity Read ↗

Differential genotype dependent inhibition of CYP2C9 in humans.Semantic proximity Read ↗

Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.